Stephan Ortiz

1.4k total citations
37 papers, 810 citations indexed

About

Stephan Ortiz is a scholar working on Immunology, Nephrology and Hematology. According to data from OpenAlex, Stephan Ortiz has authored 37 papers receiving a total of 810 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 11 papers in Nephrology and 10 papers in Hematology. Recurrent topics in Stephan Ortiz's work include Complement system in diseases (17 papers), Renal Diseases and Glomerulopathies (11 papers) and Blood groups and transfusion (8 papers). Stephan Ortiz is often cited by papers focused on Complement system in diseases (17 papers), Renal Diseases and Glomerulopathies (11 papers) and Blood groups and transfusion (8 papers). Stephan Ortiz collaborates with scholars based in United States, France and Spain. Stephan Ortiz's co-authors include Austin Kulasekararaj, Régis Peffault de Latour, Jeff Szer, Scott T. Rottinghaus, Antonio M. Risitano, Jong Wook Lee, Alexander Röth, Richard A. Wells, Caroline Piatek and Lori Shafner and has published in prestigious journals such as Blood, Neurology and Kidney International.

In The Last Decade

Stephan Ortiz

37 papers receiving 783 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephan Ortiz United States 15 548 351 193 162 139 37 810
Kimberly P. Briley United States 15 339 0.6× 305 0.9× 56 0.3× 36 0.2× 13 0.1× 28 1.2k
J.L. Moake United States 11 229 0.4× 83 0.2× 338 1.8× 127 0.8× 7 0.1× 22 565
Eiji Ishikawa Japan 12 70 0.1× 227 0.6× 99 0.5× 55 0.3× 12 0.1× 65 611
Robert B. Huizinga United States 12 245 0.4× 210 0.6× 22 0.1× 17 0.1× 20 0.1× 33 709
Lidia Ghisdal Belgium 16 100 0.2× 68 0.2× 47 0.2× 27 0.2× 33 0.2× 24 816
Jeremy S. Leventhal United States 14 139 0.3× 200 0.6× 14 0.1× 25 0.2× 10 0.1× 20 562
Calogero Lino Cirami Italy 12 93 0.2× 133 0.4× 38 0.2× 23 0.1× 3 0.0× 37 499
Brian Susskind United States 15 304 0.6× 146 0.4× 112 0.6× 21 0.1× 11 0.1× 36 1.3k
John Rogosheske United States 17 80 0.1× 14 0.0× 358 1.9× 45 0.3× 22 0.2× 34 693
Edward Bourry France 10 85 0.2× 129 0.4× 38 0.2× 49 0.3× 4 0.0× 16 359

Countries citing papers authored by Stephan Ortiz

Since Specialization
Citations

This map shows the geographic impact of Stephan Ortiz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Ortiz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Ortiz more than expected).

Fields of papers citing papers by Stephan Ortiz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Ortiz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Ortiz. The network helps show where Stephan Ortiz may publish in the future.

Co-authorship network of co-authors of Stephan Ortiz

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Ortiz. A scholar is included among the top collaborators of Stephan Ortiz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Ortiz. Stephan Ortiz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Vu, Tuan, Stephan Ortiz, Masahisa Katsuno, et al.. (2023). Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. Journal of Neurology. 270(6). 3129–3137. 26 indexed citations
3.
Piatek, Caroline, Flore Sicre de Fontbrune, Fahri Şahin, et al.. (2023). Efficacy and Safety of Subcutaneous Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Prior Intravenous Eculizumab: 2-Year Follow-up. Blood. 142(Supplement 1). 2713–2713. 1 indexed citations
4.
Yenerel, Mustafa Nuri, Flore Sicre de Fontbrune, Caroline Piatek, et al.. (2022). Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up. Advances in Therapy. 40(1). 211–232. 17 indexed citations
5.
Vu, Tuan, Stephan Ortiz, Masahisa Katsuno, et al.. (2022). Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Study (P3-1.002). Neurology. 98(18_supplement). 2 indexed citations
6.
McEneny‐King, Alanna, Jonathan Monteleone, Shamsah Kazani, & Stephan Ortiz. (2021). Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019. Infectious Diseases and Therapy. 10(2). 1045–1054. 15 indexed citations
7.
Ariceta, Gema, Bradley P. Dixon, Seong Heon Kim, et al.. (2020). The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney International. 100(1). 225–237. 58 indexed citations
8.
Brodsky, Robert A., Régis Peffault de Latour, Scott T. Rottinghaus, et al.. (2020). Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 106(1). 230–237. 83 indexed citations
9.
Tanaka, Kazuki, Brigitte Adams, Naoya Fujita, et al.. (2020). Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatric Nephrology. 36(4). 1033–1033. 1 indexed citations
10.
Schrezenmeier, Hubert, Austin Kulasekararaj, L. Mitchell, et al.. (2019). S863 ONE-YEAR EFFICACY OF RAVULIZUMAB (ALXN1210) IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAIVE TO COMPLEMENT INHIBITORS. HemaSphere. 3(S1). 385–386. 2 indexed citations
11.
Cataland, Spero, Gema Ariceta, Peter Chen, et al.. (2019). Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab. Blood. 134(Supplement_1). 1099–1099. 14 indexed citations
12.
Kulasekararaj, Austin, Anita Hill, Scott T. Rottinghaus, et al.. (2018). Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study. Blood. 133(6). 540–549. 256 indexed citations
13.
14.
15.
16.
Lasseter, Kenneth C., et al.. (2012). Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulmonary Pharmacology & Therapeutics. 25(2). 193–199. 23 indexed citations
17.
Ortiz, Stephan, Stephen Flach, Cynthia Caracta, Esther García Gil, & Josep M. Jansat. (2011). Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants. The Journal of Clinical Pharmacology. 52(6). 819–827. 12 indexed citations
18.
Lindamood, Charles, et al.. (2010). Effects of Commonly Administered Agents and Genetics on Nebivolol Pharmacokinetics: Drug-Drug Interaction Studies. The Journal of Clinical Pharmacology. 51(4). 575–585. 25 indexed citations
19.
Schmid‐Zalaudek, Karin, Sílvia Pascual, Esther García Gil, Stephan Ortiz, & Josep M. Jansat. (2010). Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial. Clinical Therapeutics. 32(10). 1798–1812. 27 indexed citations
20.
Almoazen, Hassan, et al.. (2001). Alternative high-performance liquid chromatographic assay for p-aminohippuric acid (PAH): effect of aging on PAH excretion in the isolated perfused rat kidney. Journal of Pharmaceutical and Biomedical Analysis. 26(5-6). 687–699. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kimberly P. Briley Breakdown of academic impact, for papers by J.L. Moake Breakdown of academic impact, for papers by Eiji Ishikawa Breakdown of academic impact, for papers by Robert B. Huizinga Breakdown of academic impact, for papers by Lidia Ghisdal Breakdown of academic impact, for papers by Jeremy S. Leventhal Breakdown of academic impact, for papers by Calogero Lino Cirami Breakdown of academic impact, for papers by Brian Susskind Breakdown of academic impact, for papers by John Rogosheske Breakdown of academic impact, for papers by Edward Bourry
Rankless by CCL
2026